Profil
Emmanuelle Charpentier is the founder of CRISPR Therapeutics AG, founded in 2013, and ERS Genomics Ltd., founded in 2014.
At ERS Genomics Ltd., she holds the title of Scientific Advisor, which she has held since 2014.
Postes actifs de Emmanuelle Charpentier
| Sociétés | Poste | Début |
|---|---|---|
ERS Genomics Ltd.
 ERS Genomics Ltd. BiotechnologyHealth Technology ERS Genomic Ltd. engages in the development of biotechnology. It was formed to provide broad access to the foundational CRISPR-Cas9, a new genome editing technology, which offers speed, efficiency, and cost over earlier genome editing methods. The company was founded by Emmanuelle Charpentier and Shaun Foy in 2014 and is headquartered in Dublin, Ireland. | Fondateur | 01/01/2014 |
Anciens postes connus de Emmanuelle Charpentier
| Sociétés | Poste | Fin |
|---|---|---|
| CRISPR THERAPEUTICS AG | Fondateur | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CRISPR THERAPEUTICS AG | Health Technology |
| Entreprise privées | 1 |
|---|---|
ERS Genomics Ltd.
ERS Genomics Ltd. BiotechnologyHealth Technology ERS Genomic Ltd. engages in the development of biotechnology. It was formed to provide broad access to the foundational CRISPR-Cas9, a new genome editing technology, which offers speed, efficiency, and cost over earlier genome editing methods. The company was founded by Emmanuelle Charpentier and Shaun Foy in 2014 and is headquartered in Dublin, Ireland. | Health Technology |
